Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 51 articles:
HTML format
Text format



Single Articles


    October 2018
  1. LEDERMANN JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, et al
    Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed     Text format    


    July 2018
  2. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  3. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    PubMed     Text format    


    May 2018
  5. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. MARTH C, Landoni F, Mahner S, McCormack M, et al
    Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 May 5. pii: 4993205. doi: 10.1093.
    PubMed     Text format    


    April 2018
  7. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    PubMed     Text format    


  8. CREUTZBERG CL, Bosse T
    Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?
    Ann Oncol. 2018 Apr 14. pii: 4970554. doi: 10.1093.
    PubMed     Text format    


    March 2018
  9. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  10. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. KOMMOSS S, McConechy MK, Kommoss F, Leung S, et al
    Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series.
    Ann Oncol. 2018 Feb 7. pii: 4844033. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  15. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  17. DE BOER SM, Wortman BG, Bosse T, Powell ME, et al
    Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
    Ann Oncol. 2017 Nov 27. pii: 4668721. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. OKTAY K, Taylan E, Rodriguez-Wallberg KA, Bedoschi G, et al
    Goserelin Does Not Preserve Ovarian Function Against Chemotherapy-Induced Damage.
    Ann Oncol. 2017 Nov 3. doi: 10.1093.
    PubMed     Text format    


  20. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  21. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  22. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  23. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  24. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  25. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  26. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  27. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  28. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  29. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  30. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  31. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Text format     Abstract available


    October 2017
  32. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  33. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  34. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


    March 2017
  36. THAKER PH, Salani R, Brady WE, Lankes HA, et al
    A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Ann Oncol. 2017;28:505-511.
    PubMed     Text format     Abstract available


    April 2016
  37. DI MAIO M, Perrone F
    Lessons from clinical trials on quality of life assessment in ovarian cancer trials.
    Ann Oncol. 2016.
    PubMed     Text format    


  38. FRIEDLANDER M, Mercieca-Bebber RL, King MT
    Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
    Ann Oncol. 2016;27 Suppl 1:i66-i71.
    PubMed     Text format     Abstract available


  39. PUJADE-LAURAINE E, Combe P
    Recurrent ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i63-i65.
    PubMed     Text format     Abstract available


  40. BOOKMAN MA
    Optimal primary therapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i58-i62.
    PubMed     Text format     Abstract available


  41. LEDERMANN JA
    PARP inhibitors in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i40-i44.
    PubMed     Text format     Abstract available


  42. KRZYSTYNIAK J, Ceppi L, Dizon DS, Birrer MJ, et al
    Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i4-i10.
    PubMed     Text format     Abstract available


  43. MONK BJ, Minion LE, Coleman RL
    Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Ann Oncol. 2016;27 Suppl 1:i33-i39.
    PubMed     Text format     Abstract available


  44. MAHNER S, Trillsch F, Chi D, Harter P, et al
    Neoadjuvant chemotherapy in ovarian cancer revisited.
    Ann Oncol. 2016;27 Suppl 1:i30-i32.
    PubMed     Text format     Abstract available


  45. REYNERS AK, Broekman KE, Glaudemans AW, Brouwers AH, et al
    Molecular imaging in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i23-i29.
    PubMed     Text format     Abstract available


  46. COUKOS G, Tanyi J, Kandalaft LE
    Opportunities in immunotherapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i11-i15.
    PubMed     Text format     Abstract available


  47. KAYE SB
    Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Ann Oncol. 2016;27 Suppl 1:i1-i3.
    PubMed     Text format     Abstract available


  48. POVEDA A, Romero I
    Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Ann Oncol. 2016;27 Suppl 1:i72-i73.
    PubMed     Text format    


    March 2016
  49. MOSCHETTA M, George A, Kaye SB, Banerjee S, et al
    BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  50. FUJIWARA K, Monk BJ, Lhomme C, Coleman RL, et al
    Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  51. MATULONIS UA, Penson RT, Domchek SM, Kaufman B, et al
    Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: